Radiation Oncology/Endometrium/GOG Endometrium

From Wikibooks, open books for an open world
< Radiation Oncology‎ | Endometrium
Jump to: navigation, search

Endometrial Cancer: GOG OPEN TRIALS
Number Title
GOG-0258 Phase III Randomized Study of Adjuvant Chemoradiotherapy Comprising Cisplatin and Tumor Volume-Directed Radiotherapy Followed by Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel Alone in Patients With Stage III or IVA Endometrial Carcinoma
GOG-0249 Phase III Randomized Study of Pelvic Radiotherapy Versus Vaginal Cuff Brachytherapy, Paclitaxel, and Carboplatin in Patients With High-Risk Stage I or II Endometrial Carcinoma
GOG-0247 Study of Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Completion of Treatment in Patients With Primary or Recurrent Invasive Carcinoma of the Uterine Corpus or Uterine Cervix
GOG-0244 Prospective Study of the Incidence, Risk Factors, and Impact of Lymphedema After Radical Surgery in Patients With Stage I-II Endometrial (Uterine) Cancer, Stage IA-IIA Cervical Cancer, or Stage I-IV Vulvar Cancer
GOG-0238 Phase II Randomized Study of Pelvic Radiotherapy With Versus Without Cisplatin in Patients With Recurrent Endometrial Cancer
GOG-0233 Phase I/II Study of the Utility of Preoperative Fludeoxyglucose F 18 Positron Emission Tomography/CT Scanning and Ferumoxtran-10 MRI Scanning Prior to Primary Chemoradiotherapy in Detecting Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix or High-Risk Endometrial Carcinoma
GOG-0229H Phase II Study of MEK inhibitor AZD6244 in Patients With Recurrent or Persistent Endometrial Carcinoma
GOG-0210 Study to Collect Clinical Specimens For Molecular Staging of Endometrial Carcinoma
GOG-0136 Research Study of Collection of Gynecological Tumor Specimens
GOG-0086P Phase II Randomized Study of Paclitaxel, Carboplatin, and Bevacizumab Versus Paclitaxel, Carboplatin, and Temsirolimus Versus Ixabepilone, Carboplatin, and Bevacizumab in Patients With Stage III-IV or Recurrent Endometrial Cancer
GOG-9920 Phase I Study of Doxorubicin Hydrochloride in Combination With Intraperitoneal (IP) Paclitaxel and Intravenous or IP Cisplatin in Patients With Endometrial Cancer At High Risk for Peritoneal Failure


Endometrial Cancer: GOG CLOSED TRIALS INVOLVING RADIATION
Number Title Publication
GOG-0184 Phase III Randomized Adjuvant Study of Tumor Volume-Directed Pelvic Radiotherapy With or Without Paraaortic Radiotherapy Followed By Cisplatin and Doxorubicin With or Without Paclitaxel in Patients With Stage III Endometrial Carcinoma PMID 19108877
GOG-0156 Phase III Randomized Study of Adjuvant Pelvic Irradiation vs DOX/CDDP for Stage IB/IC/IIA/IIB Endometrial Carcinoma Terminated
GOG-9908 Phase I Study of Doxorubicin and Cisplatin Followed By Whole Abdominal Radiotherapy in Patients With Stage III or IV Endometrial Cancer PMID 19135232
GOG-9907 Phase I Study of Paclitaxel and Cisplatin With Radiotherapy in Patients With Stage III or IV Endometrial Cancer PMID 18962846
GOG-9905 Phase III Randomized Study of Adjuvant Radiotherapy With or Without Cisplatin and Paclitaxel After Total Abdominal Hysterectomy and Bilateral Salpingo-oophorectomy in Patients With Stage I or II Endometrial Cancer (also RTOG 9905) Terminated
GOG-9403 Phase I Dose-Seeking Study of TAX Administered During Pelvic Irradiation for Advanced or Recurrent Cancer of the Cervix, Vagina, Endometrium, or Bladder  
GOG-9301 Phase I Study of Weekly CDDP and Whole-Abdominal Radiotherapy Followed by DOX/CDDP in Patients with Stage III/IV Endometrial Carcinoma PMID 15385116
GOG-147 Companion Protocol to Evaluate the Quality of Life in Patients with Advanced Endometrial Cancer Simultaneously Enrolled on GOG-122  
GOG-122 Phase III Randomized Trial of Whole-Abdominal Irradiation vs DOX/CDDP in Patients Who Have Undergone Maximum Debulking of Advanced Endometrial Carcinoma PMID 16330675
GOG-99 Phase III Randomized Evaluation of Adjuvant Postoperative Pelvic Radiotherapy vs No Adjuvant Therapy for Surgical Stage I and Occult Stage II Intermediate-Risk Endometrial Carcinoma PMID 14984936
GOG-94 Phase II Study of Whole-Abdominal Radiotherapy in Patients with Papillary Serous Carcinoma and Clear Cell Carcinoma of the Endometrium or with Maximally Debulked Advanced Endometrial Carcinoma PMID 16213007
GOG-18 Multimodality Therapy with Surgery and Radiotherapy for Stage II Adenocarcinoma and Adeno-Acanthoma of the Endometrium Terminated
GOG-17 Radiotherapy plus Endocrine Therapy with Progestin for Stage III and Stage IV Adenocarcinoma of the Endometrium Terminated
GOG-16 Preoperative vs Postoperative Radiotherapy Adjunctive to Surgery for Stage I Adenocarcinoma of the Endometrium Terminated


Endometrial Cancer: GOG CLOSED TRIALS
Number Title Publication
GOG-0248 Phase II Randomized Study of Temsirolimus With or Without Hormonal Therapy Comprising Megestrol Acetate and Tamoxifen Citrate in Patients With Advanced, Persistent, or Recurrent Endometrial Carcinoma  
GOG-0229I Phase II Study of Brivanib Alaninate in Patients With Recurrent or Persistent Endometrial Carcinoma  
GOG-0229G Phase II Study of Bevacizumab and Temsirolimus in Patients With Recurrent or Persistent Endometrial Carcinoma  
GOG-0229F Phase II Study of VEGF Trap in Patients With Recurrent or Persistent Endometrial Carcinoma  
GOG-0229E Phase II Study of Bevacizumab in Patients With Recurrent or Persistent Endometrial Cancer  
GOG-0229D Phase II Study of Lapatinib in Patients With Recurrent or Persistent Endometrial Carcinoma  
GOG-0229C Phase II Study of Gefitinib in Patients With Persistent or Recurrent Endometrial Carcinoma  
GOG-0229B Phase II Study of Thalidomide in Patients With Recurrent or Persistent Endometrial Cancer PMID 17306350
GOG-0224 Phase II Randomized Study of Megestrol Acetate in Patients With Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia  
GOG-0211 Phase II Pilot Study of Medroxyprogesterone in Patients With Endometrioid Adenocarcinoma of the Uterine Corpus  
GOG-0209 Phase III Randomized Study of Doxorubicin, Cisplatin, Paclitaxel, and Filgrastim (G-CSF) Versus Carboplatin and Paclitaxel in Patients With Stage III or IV or Recurrent Endometrial Cancer  
GOG-0189 Phase III Randomized Study of Doxorubicin, Cisplatin, Paclitaxel, and Filgrastim (G-CSF) Versus Tamoxifen and Megestrol in Patients With Stage III or IV or Recurrent Endometrial Cancer  
GOG-0188 Phase II Study of Fulvestrant in Patients With Newly Recurrent, Persistent, or Metastatic Endometrial Cancer  
GOG-0184 Phase III Randomized Adjuvant Study of Tumor Volume-Directed Pelvic Radiotherapy With or Without Paraaortic Radiotherapy Followed By Cisplatin and Doxorubicin With or Without Paclitaxel in Patients With Stage III Endometrial Carcinoma  
GOG-0181B Phase II Study of Trastuzumab (Herceptin®) in Patients With Advanced, Recurrent, or Persistent Endometrial Adenocarcinoma PMID 1984088
GOG-0177 Phase III Randomized Study of Doxorubicin/Cisplatin With or Without Paclitaxel and Filgrastim (G-CSF) Support in Patients with Stage III, Stage IV, or Recurrent Endometrial Cancer  
GOG-0163 Phase III Randomized Study of Doxorubicin/Cisplatin vs Doxorubicin/Paclitaxel/G-CSF for Primary Stage III/IV or Recurrent Endometrial Carcinoma  
GOG-0156 Phase III Randomized Study of Adjuvant Pelvic Irradiation vs DOX/CDDP for Stage IB/IC/IIA/IIB Endometrial Carcinoma Terminated
GOG-0137A Phase III Randomized Study of Estrogen Replacement Therapy Versus Placebo in Women With Stage I or II Endometrial Adenocarcinoma  
GOG-0129Q] Phase II Study of Gemcitabine Hydrochloride in Patients With Recurrent or Persistent Endometrial Adenocarcinoma  
GOG-0129P Phase II Study of Ixabepilone in Patients With Recurrent or Persistent Endometrial Adenocarcinoma PMID 19451430
GOG-0129O Phase II Study of Pemetrexed Disodium in Patients With Persistent or Recurrent Endometrial Adenocarcinoma PMID 19804902
GOG-0129N Phase II Study of Docetaxel in Patients With Recurrent or Persistent Endometrial Carcinoma PMID 18675446
GOG-0129M Phase II Study of Flavopiridol in Patients With Recurrent or Persistent Endometrial Carcinoma PMID 15978659
GOG-0129K Phase II Study of Oxaliplatin in Patients With Persistent or Recurrent Endometrial Carcinoma PMID 16712905
GOG-0087J Phase II Study of Doxorubicin HCl Liposome in Patients With Recurrent or Advanced Uterine Sarcoma PMID 15721421
GOG-0086M Phase II Study of Doxorubicin HCl Liposome in Patients With Advanced or Recurrent Endometrial Cancer PMID 15975638
GOG-0026A Master Protocol Template for Individual Phase II Studies of New Drug Therapies in Patients With Metastatic or Recurrent Gynecologic Malignancies  
GOG-9908 Phase I Study of Doxorubicin and Cisplatin Followed By Whole Abdominal Radiotherapy in Patients With Stage III or IV Endometrial Cancer PMID 19135232
GOG-9907 Phase I Study of Paclitaxel and Cisplatin With Radiotherapy in Patients With Stage III or IV Endometrial Cancer PMID 18962846
GOG-9905 Phase III Randomized Study of Adjuvant Radiotherapy With or Without Cisplatin and Paclitaxel After Total Abdominal Hysterectomy and Bilateral Salpingo-oophorectomy in Patients With Stage I or II Endometrial Cancer (also RTOG 9905) Terminated
GOG-9902 Quality of Life of Gynecologic Cancer Survivors  
GOG-9805 Phase II Study of Amifostine for Protection Against Cisplatin and Paclitaxel Induced Neurotoxicity in Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer PMID 14615449
GOG-9405 Phase I Study of Paclitaxel Combined with Fixed Doses of CDDP/DOX for Advanced Gynecologic Malignancies and Recurrent Bladder Cancer with or without Pelvic Irradiation PMID 11181665
GOG-9403 Phase I Dose-Seeking Study of TAX Administered During Pelvic Irradiation for Advanced or Recurrent Cancer of the Cervix, Vagina, Endometrium, or Bladder  
GOG-9301 Phase I Study of Weekly CDDP and Whole-Abdominal Radiotherapy Followed by DOX/CDDP in Patients with Stage III/IV Endometrial Carcinoma PMID 15385116
GOG-9206 Phase II Study of Laparoscopic-Assisted Vaginal Hysterectomy/Bilateral Salpingo-Oophorectomy, Intraperitoneal Staging, and Pelvic and Aortic Lymph Node Sampling in Patients with Presumed Stage I/IIA Adenocarcinoma of the Endometrium PMID 15086735
GOG-9102 The Effect of Alopecia on the Cancer Patient's Body Image and the Role of Audiovisual Information on Improving Body Image  
GOG-9101 Phase I Study of Intraperitoneal TAX in Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma PMID 8523061
GOG-9001 Phase I Limited-Access Study of Weekly Cisplatin and Whole-Abdominal Irradiation in Patients with Stage III/IV Endometrial Carcinoma PMID 8946862
GOG-8909 Phase I Study of CDDP plus Cyclosporine in Patients with Refractory Gynecologic Cancer  
GOG-8808 Phase I Study of Intraperitoneal Taxol in Patients with Recurrent and/or Persistent Gynecologic Carcinoma PMID 7912515
GOG-7892 Phase II Hormone Therapy with Tamoxifen for Advanced or Recurrent Endometrial Adenocarcinoma Terminated
GOG-180 Phase II Study of Danazol in Patients with Advanced or Recurrent Endometrial Cancer PMID 12798713
GOG-168 Phase II Study of Anastrozole (Arimidex) in Advanced, Recurrent or Persistent Endometrial Cancer PMID 10926805
GOG-167 Prospective Study of Immediate Hysterectomy and Phase II Randomized Study of Medroxyprogesterone Acetate (Provera) Versus Medroxyprogesterone Acetate Suspension (Depo-Provera) Prior to Hysterectomy in Patients With Atypical Endometrial Hyperplasia PMID 16400639
GOG-166 Phase II Study of High-Dose Intravenous Progesterone and Doxorubicin for Progressive Endometrial Carcinoma Resistant to Ongoing Doxorubicin Alone  
GOG-159 Phase II Study of ZDX in Advanced, Recurrent, or Persistent Endometrial Cancer  
GOG-153 Phase II Study of Alternating Courses of Megestrol and Tamoxifen for Recurrent or Persistent Endometrial Adenocarcinoma PMID 14751131
GOG-147 Companion Protocol to Evaluate the Quality of Life in Patients with Advanced Endometrial Cancer Simultaneously Enrolled on GOG-122  
GOG-139 Phase III Randomized Study of DOX/CDDP Administered on Standard vs Circadian-Timed Schedules in Patients with Primary Stage III/IV/Recurrent Endometrial Carcinoma PMID 14551299
GOG-129L Phase II Study of 6-Hydroxymethylacylfulvene (Irofulven) in Patients With Persistent or Recurrent, Refractory Endometrial Carcinoma PMID 15122083
GOG-129J Phase II Study of Topotecan in Patients With Persistent, Recurrent, or Refractory Endometrial Carcinoma PMID 12468321
GOG-129I Phase II Study of Pyrazoloacridine (PZA) in Patients with Recurrent or Refractory Endometrial Carcinoma PMID 11812081
GOG-129H Phase II Study of the Effects of DOXIL in the Treatment of Recurrent or Persistent Endometrial Carcinoma PMID 11981008
GOG-129E Phase II Study of Dactinomycin for Recurrent or Persistent Endometrial Carcinoma PMID 10600310
GOG-129C Phase II Study of TAX for Recurrent or Persistent Endometrial Cancer PMID 12648575
GOG-129B Phase II Study of Prolonged Oral VP-16 in Patients with Recurrent or Advanced Endometrial Cancer  
GOG-122 Phase III Randomized Trial of Whole-Abdominal Irradiation vs DOX/CDDP in Patients Who Have Undergone Maximum Debulking of Advanced Endometrial Carcinoma PMID 16330675
GOG-121 Phase II Trial of High-Dose MEG in Patients with Advanced or Recurrent Endometrial Carcinoma  
GOG-119 Phase II Study of Tamoxifen plus Medroxyprogesterone for Advanced, Recurrent, or Metastatic Endometrial Carcinoma PMID 14751130
GOG-107 Phase III Randomized Study Comparing ADR vs ADR/CACP in Patients with Recurrent Primary Stage III/IV Endometrial Carcinoma PMID 15459211
GOG-99 Phase III Randomized Evaluation of Adjuvant Postoperative Pelvic Radiotherapy vs No Adjuvant Therapy for Surgical Stage I and Occult Stage II Intermediate-Risk Endometrial Carcinoma PMID 14984936
GOG-96 Phase II Circadian-Timed Combination Chemotherapy with ADR/CDDP in Patients with Advanced Primary Endometrial Carcinoma PMID 8256764
GOG-94 Phase II Study of Whole-Abdominal Radiotherapy in Patients with Papillary Serous Carcinoma and Clear Cell Carcinoma of the Endometrium or with Maximally Debulked Advanced Endometrial Carcinoma PMID 16213007
GOG-860 Phase II Master Protocol for Chemotherapy in Patients with Advanced or Recurrent Carcinoma of the Endometrium --- TAX/G-CSF  
GOG-86J Phase II Master Protocol for Treatment of Patients with Advanced or Recurrent Carcinoma of the Endometrium --- Tumor Necrosis Factor  
GOG-86I Phase II Study of IFF/Mesna for Advanced or Recurrent Carcinoma of the Endometrium  
GOG-86E Phase II Master Protocol for Chemotherapy in Patients with Advanced or Recurrent Carcinoma of the Endometrium --- Vincristine PMID 8424397
GOG-86D Phase II Master Protocol for Chemotherapy in Patients with Advanced or Recurrent Carcinoma of the Endometrium --- MTX PMID 2407104
GOG-86 Phase II Master Protocol for Advanced or Recurrent Carcinoma of the Endometrium: Phase I/II Study of Hexamethylmelamine PMID 3141250
GOG-083 Phase II Clinico-Pathological Study of Adjuvant Chemotherapy with L-PAM in Patients with Simultaneous Endometrial and Ovarian Carcinoma  
GOG-81F Master Protocol for Hormonal Treatment of Advanced or Recurrent Endometrial Carcinoma --- Phase II Tamoxifen for Disease Responsive to Progestins PMID 11208827
GOG-81 Phase III Randomized Study of Low-Dose vs High-Dose Medroxyprogesterone Acetate (Provera) in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma PMID 11208827
GOG-62 Data Collection Form for Extravasation Injury with Doxorubicin  
GOG-48 Phase III Provera (MPA) vs ADR vs ADR/CTX for Stage III/IV or Recurrent Endometrial Cancer PMID 8021731
GOG-28 Phase III L-PAM/5-FU/MEG Chemotherapy vs ADR/CTX/5-FU/MEG for Primary Stage III or IV Recurrent or Residual Endometrial Cancer PMID 6371627
GOG-34 Phase III Randomized Trial of Surgery plus Radiotherapy Followed by Chemotherapy with ADR vs Surgery plus Radiotherapy Alone in Patients with High-Risk Stage I/High-Risk Occult Stage II Endometrial Carcinoma, Including Those with Adnexal Metastases PMID 2298404
GOG-30 Phase II Chemotherapy with Adriamycin for Endometrial Adenocarcinoma  
GOG-26MM Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: EDAM PMID 7900709
GOG-26KK Phase II Master Protocol for Advanced, Recurrent Endometrial Carcinoma: Merbarone PMID 8554040
GOG-26HH Phase II Master Protocol for Advanced, Recurrent Pelvic Gynecologic Malignancies: Fluorouracil/Leucovorin  
GOG-26GG Phase II Master Protocol for Advanced, Recurrent Pelvic Gynecologic Malignancies: Fazarabine PMID 7534978
GOG-26Y Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: Vinblastine PMID 2239800
GOG-26W Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: Echinomycin PMID 2198794
GOG-26V Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: N-Methylformamide PMID 2384305
GOG-26T Phase II Master Protocol Chemotherapy with 4'-Deoxydoxorubicin for Advanced, Recurrent Pelvic Malignancies PMID 2557300
GOG-26P Phase II Master Protocol for Advanced, Recurrent Pelvic Malignancies: AT-125 PMID 3700040
GOG-26M Phase II Chemotherapy with PALA for Advanced Recurrent Pelvic Malignancies PMID 6731346
GOG-26K Phase II Chemotherapy with Chlorozotocin for Advanced, Recurrent and Metastatic Pelvic Malignancies in Progression  
GOG-26J Phase II Chemotherapy with YOSHI-864 for Advanced, Recurrent Pelvic Malignancies PMID 6288239
GOG-26H Phase II Chemotherapy with Maytansine for Advanced Recurrent Pelvic Malignancies PMID 6869315
GOG-26I Phase II Chemotherapy with AMSA for Advanced, Recurrent Pelvic Malignancies (Cervix) PMID 6687445
GOG-26G Phase II Master Protocol for Advanced, Recurrent Pelvic Malignancies: ICRF-159 PMID 3953488
GOG-26F Phase II Chemotherapy with Baker's Antifol for Advanced Recurrent Pelvic Malignancies PMID 6236163
GOG-26E Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: Dianhydrogalactitol PMID 6511240
GOG-26D Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: VP-16 PMID 6509456
GOG-26B Phase II Chemotherapy with Piperazinedione for Advanced Gynecologic Malignancies in Women PMID 3754086
GOG-23 Chemotherapy with ADR/VCR/CTX for Carcinoma of the Cervix and for Adenocarcinoma of the Endometrium  
GOG-18 Multimodality Therapy with Surgery and Radiotherapy for Stage II Adenocarcinoma and Adeno-Acanthoma of the Endometrium Terminated
GOG-17 Radiotherapy plus Endocrine Therapy with Progestin for Stage III and Stage IV Adenocarcinoma of the Endometrium Terminated
GOG-16 Preoperative vs Postoperative Radiotherapy Adjunctive to Surgery for Stage I Adenocarcinoma of the Endometrium Terminated
GOG-15 Modified Phase II-III Chemotherapy with CCNU or MeCCNU for Advanced Gynecologic Cancers PMID 350400
GOG-P12 Relation of Progestin Receptor Concentration to Efficacy of Progestin Therapy for Endometrial Adenocarcinoma - Pilot Study